



## Financial Tear Sheet

### Corporate Profile

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at [www.alkermes.com](http://www.alkermes.com) (<http://www.alkermes.com>).

### IR Contacts

Sandy Coombs  
Co-Head, Investor Relations  
Alkermes, Inc.

Phone: 1 781-609-6377

E-mail: [Sandra.Coombs@alkermes.com](mailto:Sandra.Coombs@alkermes.com) (<mailto:Sandra.Coombs@alkermes.com>)

Eva Stroynowski  
Co-Head, Investor Relations  
Alkermes, Inc.

Phone: 1 781-609-6823

E-mail: [eva.stroynowski@alkermes.com](mailto:eva.stroynowski@alkermes.com) (<mailto:eva.stroynowski@alkermes.com>)

### Stock Performance

ALKS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	<b>\$44.54</b>
Change (%)	0.75 (1.71%) ▲
Volume	151,771
52 Week Low	\$39.54
Market Cap	\$6,917,350,923
Rolling EPS	-0.91
PE Ratio	N/A
Shares Outstanding	155,303,000

Data as of 08/14/18 12:23 p.m. ET



### Recent Headlines & Events

08/01/18 - 4:00 p.m.

Alkermes' Corporate Presentation to be Webcast at the 38th Annual Canaccord Genuity Growth Conference ([phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2361402](https://www.edgaronline.com/phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2361402))

07/26/18 - 7:00 a.m.

Alkermes Plc Reports Second Quarter 2018 Financial Results ([phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2360206](https://www.edgaronline.com/phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2360206))

07/19/18 - 4:00 p.m.

Alkermes to Host Conference Call to Discuss Second Quarter 2018 Financial Results ([phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2359115](https://www.edgaronline.com/phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2359115))

There are currently no events scheduled.

Mean Recommendation: 2.5

Unable to fulfill request.



Sell Strong Buy

SEC Filings

Year Filter  
All Years

Corporate Governance

Richard F. Pops C  
E


Filing Date	Form		
08/03/18	4 (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2I6YXJkLmNvbS9vdXRsaW5lLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MTIzODk0Njgmc3Vic2lkPTU3JmI4YnJsPXRydWU%3d&ListAll=1)	Shane Cooke	Pi
07/26/18	S-8 (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2I6YXJkLmNvbS9vdXRsaW5lLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MTIzE4NTkmc3Vic2lkPTU3JmI4YnJsPXRydWU%3d&ListAll=1)		
07/26/18	10-Q (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2I6YXJkLmNvbS9vdXRsaW5lLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MTIzNzA1NzQmc3Vic2lkPTU3JmI4YnJsPXRydWU%3d&ListAll=1&sXBRL=1)	Kathryn L. Biberstein	S C C O AI
07/26/18	8-K (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2I6YXJkLmNvbS9vdXRsaW5lLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MTIzNzA1NzQmc3Vic2lkPTU3JmI4YnJsPXRydWU%3d&ListAll=1)	Madeline D. Coffin	Vi R
		Elliot W. Ehrich, M.D.E.	Pi D M
		James M. Frates	S C
		Georgianna Harris, Ph.D.	Vi R
		Blair C. Jackson	Vi D
		Michael J. Landine	S C
		Mark Namchuk, Ph.D.	S R ar D
		Peter Norman	Vi G A
		Rebecca J. Peterson	S C C
		Gordon G. Pugh	S C ar
		Srdjan Stankovic, M.D., MSPH	S C M
		Mark Stejbach	S C O



Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	0	.00	0.0	0
Mutual Fund	0	.00	0.0	0
Insider *	0	.00	0.0	0

\*Insider values reflect direct beneficial ownership.

Powered by  Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed